Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB).
The company said Harris, who previously worked at NASA, serves as CEO and managing partner of Vesalius Ventures, Inc, a venture capital firm that supports and invests in early-to-mid-stage healthcare companies.
“As we continue to advance our mission to be a leader in the rapidly growing field of AI-driven drug discovery, with a unique portfolio of assets and capabilities that includes an extensive biobank of heterogeneous tumor samples and CLIA lab, we can benefit from a broad range of backgrounds and perspectives,” Predictive Oncology CEO Raymond Vennare said in a statement.
“Dr Harris brings a wealth of clinical, business and operational healthcare expertise to our BAB, and I look forward to his contributions as we pursue both existing and new opportunities for our technology,” he added.
Predictive Oncology also noted that Harris serves on several boards of directors, including Raytheon Technologies, US Physical Therapy, Massachusetts Mutual Life Insurance Company (MassMutual) and the Texas Medical Center.
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide.
Contact Sean at sean@proactiveinvestors.com